Home > News > Rituximab for the Treatment of Graves’ Orbitopathy
Thyroid Disorders
Read Time: 11 mins

Rituximab for the Treatment of Graves’ Orbitopathy

Published Online: March 20th 2012 US Endocrinology, 2011;7(2):130-6 DOI: http://doi.org/10.17925/USE.2011.07.02.130
Authors: Mario Salvi, Guia Vannucchi, Paolo Beck-Peccoz
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

The contribution of B-cells to human autoimmune disease has recently been underscored because of the therapeutic benefit of B-cell depleting therapies. B-cells are involved in the production of autoantibodies, and in CD4+ T-cell activation, control of T-cell function, and inflammation through cytokine production. B-cells are also important antigen-presenting cells. Rituximab (RTX) has been used off-label in various autoimmune disorders and has been shown to effectively deplete mature and memory CD20+ B-cells, but not long-lived plasma cells. The rationale behind the use of RTX in Graves’ disease (GD) and Graves’ orbitopathy (GO) relies on its putative effect on pathogenic autoantibodies causing hyperthyroidism. RTX in patients with active GO has been shown to have a significant effect on the inflammatory activity and severity of GO. However, caution is suggested before proposing RTX as a novel therapeutic tool in this disease until randomized controlled trials are available. Should preliminary observations be confirmed, an optimal strategy for controlling the progression of GO would be to pursue B-cell depletion shortly after diagnosis, rather than only as an alternative therapeutic option when standard immunosuppression has failed.

Keywords

Graves

Article:

Functions of B Cells and Their Role in Autoimmune Disease

Functions of B Cells and Their Role in Autoimmune Disease
Although B lymphocytes are known to contribute to the pathogenesis of autoimmune disease through autoantibody production,1 many recent studies of B-cell function carried out in experimental animal models have shown that they possess other functions such as CD4+ T-cell activation2 and control of T-cell function and inflammation through cytokine production. B cells in fact are involved in multiple pathways of the immune system in autoimmune disease by combining their multipurpose cellular and humoral functions (see Figure 1).3 B-cell contributions to human autoimmune disease have recently been reconsidered due to the therapeutic benefit of B-cell depleting therapies.4

Antibody Production
Antigens generally activate mature B cells to generate antibody secreting plasmablasts, and short-lived plasma cells that secrete antigen-specific antibodies.5 Following antigen-specific proliferation, B cells enter into the germinal center microenvironment, where they diversify their antigen receptors and generate pools of long-lived memory B cells6 that are responsible for producing and maintaining serum antibody levels.7 In autoimmune diseases, autoantibodies may be pathogenic through direct binding to specific receptors (e.g. the thyroid stimulating hormone receptor [TSHR] on the thyrocyte membrane in Graves’ disease[GD]) or through the formation of immune-complexes in tissues that locally activate complement reactions and induce inflammation.

Antigen Presentation and Co-stimulation
B cells are important antigen-presenting cells in the initiation of immune responses.8,9 Autoantigen stimulation in B-cell-depleted mice results in reduced antigen-specific CD4+ T-cell activation, which underscores that B cells contribute to the initiation of autoimmune reaction.10 Effects on Lymphoid Tissue Neogenesis and Production of Cytokines
B cells are also involved in lymphoid tissue formation11 and in mice, after B-cell depletion, it is not possible to identify lymphoid follicles within the spleens.12 Furthermore, B cells produce numerous cytokines including interleukin (IL)-10, IL-4, IL-6, lymphotoxin-α, transforming growth factor-beta (TGF-β and interferon-gamma [IFN-γ]).13

Regulatory B Cells
Regulatory B cells (B regs) or B10 cells are an IL-10-producing subset of B-cells.14 Studies in mice indicate that IL-10-producing B cells play important roles in the suppression of autoimmune and inflammatory disease. IL-10 produced by B cells has been shown to downregulate autoreactive immune mechanisms in collagen-induced arthritis14 and inflammatory bowel disease.15 As a consequence, B-cell elimination using rituximab (RTX) was in fact associated with exacerbation of ulcerative colitis16,17 and psoriasis,18 both conditions representing Th1-mediated autoimmune conditions.

B-cell Depletion with Rituximab
RTX, a chimeric mouse-human monoclonal antibody targeting the CD20 antigen, has been used off label in various autoimmune disorders but is approved for clinical use only in non-Hodgkin’s lymphoma and for the treatment of moderate-to-severe rheumatoid arthritis (RA) in patients who did not respond to TNF inhibitors. RTX depletes more than 95 % of mature B cells in blood and primary lymphoid organs after two days by a single RTX treatment in mice. CD20 is a human B lymphocyte-specific antigen expressed on immature to mature B cells, as well as memory B cells but not on stem cells and B cell precursors. Most importantly, CD20 is not expressed on antibody-producing plasma cells (see Figure 2).19 As a consequence, therapeutic targeting of CD20+ cells removes B lymphocytes in all intermediate stages of B cell maturation and, in addition, activated memory B and short-lived plasma cells by depleting their immediate precursors. Peripheral short-lived plasma cells return almost to baseline levels six to 10 months after treatment, at the time of B cell repopulation. As therapy does not affect B cell precursors or long-lived plasma cells residing in the bone marrow,20,21 antibody production is maintained over a long period of time, even without the contribution from memory cells.7,22 This is why immunoglobulin levels may not change throughout the period of peripheral B-cell depletion,23,24 even after multiple courses of treatment. In humans, it is yet to be understood whether RTX is effective for the treatment of autoimmune diseases because of its direct B-cell depleting action or by indirectly affecting autoantibody production. Consequently, novel biomarkers of its mechanism of action have to be sought. In particular, studies should address why response does not always correlate with complete B-cell depletion, as has been reported in some patients with RA.24,25

Pharmacokinetics
The majority of studies on RTX pharmacokinetics and pharmacodynamics have been performed in patients with B-cell lymphomas and have shown that serum concentration of RTX directly correlated with response and inversely correlated with tumour mass.26 Variable half-lives (11–105 hours) may thus result from the different tumour burden and also from the changes of CD20 expression in malignant B cells consequent to repeated RTX administration.27 In RA, RTX half-life has been reported to be much longer, up to 20 days after two doses of 1,000 mg, the dose being used in most autoimmune diseases,28 and the reason for this difference is not known. Dosing studies are also ultimately important in view of RTX dose costs: should lower doses in autoimmune disease be as effective as the higher doses, employed so far based on studies carried out in lymphomas, their costs would more likely be affordable by specialised clinical centres.27Safety Profile
Infusion related reactions are the most frequently reported side effects of RTX.29 Release of pro-inflammatory cytokines from macrophages, monocytes, lymphocytes and NK cells is the underlying mechanism. Additional mechanisms such as activation of complement cascade may be responsible of acute reactions caused by RTX. These reactions may be present in about 10 % of patients at first infusion, they can be severe but reversible. Among major side effects, progressive multifocal leukoencephalopathy (PML) has rarely been reported in patients receiving RTX, especially those with systemic lupus erythematosus (SLE). It is important to point out that all these patients had previously been treated with other immunosuppressive therapies including cyclophosphamide, azathioprine and even steroids, oral prednisone or intravenous methylprednisone.30,31 Since more than 40 % of cases of PML have been reported in patients with SLE who were only minimally immunosuppressed, SLE itself may be considered to predispose for PML.31

Effects of Rituximab in Graves’ Disease and Orbitopathy
Over the last five years, the potential efficacy of RTX in active GO has been sought and data derived from either case reports or uncontrolled studies have appeared in the literature. Altogether, the effects of RTX in patients with active GO have been studied in 40 patients (see Table 1) and, although the lack of inclusion of randomised and controlled patients in the studies suggests caution in generalising results, data reported show that RTX may significantly affect the inflammatory activity and the severity of GO.

The first evidence of efficacy of RTX in active GO was reported in one patient unresponsive to standard intravenous methylprednisolone therapy.32 She was euthyroid on methyl mecapto-imidazole (MMI) and had well-controlled type 1 diabetes. The clinical response was characterised by a consistent decrease of the clinical activity scores (CAS) (<3) and improvement of ocular motility, but not of hyperthyroidism. In fact, she had a surprisingly sudden relapse of hyperthyroidism, characterised by a dramatic surge of serum TSH receptor antibodies (TRAb) (>85 IU/L), while being B-cell depleted. She eventually underwent thyroidectomy. RTX induced peripheral B-cell depletion for up to six months after two intravenous doses of 1,000 mg and intra-orbital B and T cell depletion at 10 months (see below). El Fassi et al.33 treated two women with active GO, also resistant to glucocorticoid therapy, with four weekly doses of RTX of 375 mg/m2. At eight months after treatment, the CAS had decreased from five and six to one and two, respectively, and soft tissue changes, eye motility and proptosis significantly improved in both patients. In both reports the anti-inflammatory effect of RTX was observed as early as four to six weeks after therapy and persisted without disease relapse and any additional therapy. Unfortunately, case reports cannot tell us whether the disease improvement is due specifically to the drug employed or to spontaneous evolution of the disease’s natural course towards inactivation. On the other hand, while patients from these reports were unresponsive to repeated cycles of infusions of high doses methylprednisolone, they did improve rapidly and in a stable and consistent way after only two doses of RTX, suggesting that the drug did impact the active phase of the disease.

Subsequently, Salvi et al.34 conducted an open study and treated with 1 g RTX twice, with a two-week interval, a group of nine patients with active GO, of whom two had mild GO with only lid signs, and compared with a group of 20 patients treated with the standard intravenous methylprednisolone therapy. All patients responded to RTX therapy compared to 80 % of those treated with steroids (see Table 2). CAS values significantly decreased from 4.7 to 1.8 at the end of follow-up and more rapidly compared with steroids. Proptosis, eye muscle motility and signs of soft tissue inflammation also improved significantly in response to RTX. Relapse of active GO was not observed in patients treated with RTX, but occurred in 10 % of those treated with steroids, who also experienced adverse effects more frequently (45 % versus 33 % of patients) (see Table 2). More recent data have confirmed the therapeutic effects of RTX in active GO. Khanna et al.35 have reported that in six patients with active and severe GO, unresponsive to glucocorticoid therapy, RTX had a rapid and sustained therapeutic effect on both activity and severity. In this study, RTX was also infused intravenously as 1 g twice with a two-week interval, along with steroid therapy. The CAS decreased from 5.5 to 1.8 at eight weeks after RTX and remained low at six months. No patients showed improvement of extra-ocular motility or proptosis, but in four of these patients who had optic neuropathy, visual acuity improved within four weeks and returned to pre-morbid values at eight weeks from treatment. Tapering of glucocorticoids after RTX treatment was not followed by relapse of inflammatory signs. Two patients experienced minor side effects and one had sudden cardiac death later on, unlikely related to such treatment. Another recent open study conducted by Silkiss et al.36 has shown significant improvement of active GO in 12 patients after RTX administered at the dose of 1 g, two weeks apart. The mean CAS decreased from 5.5 to 1.9 at 16 weeks as well as the mean Thyroid Associated Ophthalmopathy Scale (TAOS), modified by Dolman and Rootman (VISA Classification),37 from 10.4 to 7.1. Improvement was further recorded up to 52 weeks of follow-up without evidence of relapse of inflammatory signs. Interestingly, no side effects were reported. There has been an unpublished report of an ongoing open study in Newcastle, UK by Mitchell et al.,38 in which RTX has been administered, even at a lower dose of 500 mg twice, to six patients with active GO refractory to steroid treatment. GO improved fairly rapidly in five patients, with a decrease of the CAS from 5.5 to two at 16 weeks, and remained unchanged in one, without occurrence of side effects. Single patients treated with RTX have also been reported recently. A significant therapeutic effect of RTX was observed39 in one patient with active GO and stiff person syndrome and diabetes, with complete and persistent inactivation of GO and amelioration of the spastic paresis characteristic of the muscular disease. In contrast to all previous studies, failure of RTX in improving GO but subsequent progression to optic neuropathy was described in one patient,40 unresponsive to high dose steroids. It is questionable if disease deterioration was caused by the therapy: optic neuropathy in this patient might have been subclinical, due to his unresponsiveness to steroids, and RTX was perhaps given too late to prevent further progression of GO severity. Besides being limited in their number, GO patients treated with RTX so far also had different thyroid status, baseline severity of GO and previous, often unsatisfactory immunosuppressive treatment. A novel treatment for GO is most needed, and only controlled studies will provide evidence on the efficacy and safety of RTX. These studies will also help us in deciding whether RTX is to be used as a first-line therapy in any patients with active GO or only in those with otherwise unresponsive disease of severe degree.

A potentially successful and different approach to this treatment is suggested by a very recent report from Salvi et al. who observed that the doses of RTX currently used in treating GO may be uselessly excessive.41 For the first time the author found that a low dose of RTX (100 mg) caused effective peripheral B-cell depletion and induced long-term remission of GO, without further treatment. There have been no data previously reported in the literature on the time required to attain total B-cell depletion after RTX infusion in autoimmune disease. This observation was made after discontinuing RTX in two patients because of an important infusion-related reaction. The patients described had mean baseline CAS of 5.3 which decreased to 1.6 at 16 weeks after 100 mg RTX, similarly to what has been reported after treatment with the full dose of 2,000 mg. The amelioration of GO was stable during follow-up. A study employing low dose RTX is now ongoing on a larger group of patients and is aimed at confirming such preliminary unexpected findings, potentially interesting also from the point of view of the safety concerns in using higher doses of a potent immunosuppressive agent like RTX. The Effect of Rituximab on Hyperthyroidism and Circulating Autoantibodies
One controlled study42 and two open studies have addressed the effect of RTX on the hyperthyroidism of GD,34,43 but data are inconsistent. In a controlled study, El Fassi et al.42 treated ten patients with newly diagnosed and untreated hyperthyroidism with methimazole (MMI) and RTX and 10 with only MMI until they became euthyroid. Within one year of follow-up in all patients treated with MMI alone, but in only six of 10 treated with MMI and RTX hyperthyroidism relapsed. Patients euthyroid at 30 months after RTX had serum TRAb levels not greater than 5 IU/L, which could be predictive of sustained remission.

Subsequently, the same authors have reported44 that RTX treatment in GD patients may favourably affect disease remission by distinctively acting on the TSAb subpopulation with TRAb. In that study, an 84 % decrease in cAMP production by TSH receptor-transfected CHO cells was obtained with sera from patients treated with RTX after 20 weeks, but not with sera from patients treated with MMI. In explaining these findings the author postulated that RTX may affect specifically autoreactive short-lived TSAb-producing plasma cells.45 Unfortunately, in this study peripheral B cells after RTX therapy were not measured and changes in serum TRAb and other autoantibodies could not be studied in relation to B-cell depletion or return in the peripheral blood.46 The open study of Salvi et al.34 mainly addressed the therapeutic potential of RTX in active GO. They nevertheless reported a decrease of serum TRAb levels in both RTX- and glucocorticoid-treated patients with active GO after 30 weeks, but the change was not significantly related to the time elapsed from therapy and did not correlate with either peripheral B-cell depletion or repopulation. Follow-up was at 12 months after RTX in eight patients and five months in one. RTX did not affect thyroid function, since GD patients who were hyperthyroid and untreated showed no improvement in their thyroid function and had to be started on MMI. In a recent follow-up study, Vannucchi et al.47 could not demonstrate a distinct effect of RTX on serum thyroid stimulating antibody (TSAb) autoantibodies, also measured as immunoglobin (Ig)-stimulation of cAMP by TSH receptor-transfected CHO cells, which appeared to be unchanged and to fluctuate with an identical pattern compared with serum TRAb in either hyperthyroid or euthyroid GD patients. These discrepancies may be due to a too-small number of patients’ sera with sufficiently high TRAb levels for an accurate analysis and possibly to the heterogeneity of the clinical characteristics of the patients included in these studies, i.e. thyroid function, duration of disease and presence or absence of GO. Again, larger and controlled studies are needed before drawing significant conclusions. Serum antithyroperoxidase (TPOAb) and antithyroglobulin antibodies (TgAb) were also shown to decline after RTX therapy,34 but the change was not significant and did not correlated to either B-cell depletion or return in the peripheral blood. Similar data were reported by El Fassi et al.,42 who were not able to observe a change of serum antithyroid peroxidase antibodies (TPOAb) in relation to treatment with RTX in a series of GD patients, while they did not examined TgAb. Other autoantibodies directed against putative orbital autoantigens, derived mainly from eye muscles48 have been measured in patients with active GO. No significant change from baseline was observed after RTX therapy in any of the circulating antibodies against the three orbital antigens, calsequestrin, XIII collagen and flavoprotein subunit of succinate dehydrogenase (FP-SDH), respectively.47 In an uncontrolled study, Heemstra et al.43 treated 13 patients with relapsing GD, of whom three with mild thyroid-associated ophthalmopathy (TAO) (23 %). On follow-up examination at 26 weeks after RTX, four patients had a relapse of hyperthyroidism despite RTX treatment and received radioiodine therapy, while the remaining nine patients became euthyroid and remained so for a median of 18 months. In this study, serum TRAb levels decreased significantly in nine patients, but did not correlate with B-cell depletion. Consistently with the data of El Fassi et al.,42 in the GD patients who remained euthyroid, serum TRAb level before RTX therapy were relatively low (median 4 IU/L, range 0.2–6.3). What is not explained by the results of this study is why RTX treatment would have no effect on 31 % of GD patients who were more hyperthyroid, with higher serum thyroid hormone concentrations and TRAb and eventually needed radioiodine therapy. Perhaps the lack of control subjects has prevented the author from providing a more conclusive interpretation of their findings on a potential role of RTX on GD hyperthyroidism remission rates.

Effects of Rituximab on Lymphocytes in the Peripheral Blood and Infiltrating Target Tissues
In patients with GO, data on peripheral B- and T-cell changes after RTX have been reported in the studies of Salvi et al.,32,34,49 and Heemstra et al.43 In general, RTX has been shown to induce total peripheral B-cell depletion in most patients.34,35,43 Interestingly, the clinical response to RTX in both GD43 and GO patients34 bore no clear correlation with either CD20+ cell depletion or return in the peripheral blood. When studied, B cells were not detected in the periphery at the time of second dose of 1,000 mg of RTX, at two weeks.32,34 Peripheral B-cell depletion has generally been reported to last 16–18 weeks.

Very recently, we have observed total peripheral depletion of CD20+ and CD19+ cells 45–60 minutes after infusing only 100 mg of RTX in three patients.41 Table 3 shows the B-cell depletion pattern in these patients. B-cell depletion lasted 16 weeks, similar to what we observe in patients treated with the full course of RTX therapy at the dose of 1,000 mg x 2 cycles. Typically, no changes were observed in the percentages of peripheral CD3+, CD4+ and CD8+ cells. Although most studies focus on the measurement of peripheral blood B lymphocytes before and after RTX therapy, their analysis might yield findings of limited significance because B cells in the peripheral blood represent <2 % of total mature B cells in the body.3 In addition, the self-reactive B-cell residing in the bone marrow will not be altered by RTX treatment because B cell receptor selection occurs before CD20 expression.50

Therefore, in organ-specific autoimmune disease, the therapeutic effect of RTX is likely depending on its interaction with the lymphocytic infiltrates within the target organs, e.g. the thyroid in GD and the orbit in GO. Until now, data on the effect of RTX within target organs in autoimmune disease,51 including GD and GO, are limited to studies of single case reports. While B cells have been reported to be completely absent from thyroid tissue specimens of one patient with GD one week after RTX therapy,52 in another CD20+ cells have been shown to be present in the thyroid five months after RTX.32 This discrepancy might be due to the different time of tissue sampling, since the latter study has been carried out at the time of B-cell return in the peripheral blood. Orbital tissue specimens, usually obtained at surgical decompression, have also been studied in single patients. Orbital tissue depletion of both B and T cells 10 months after RTX was firstly reported by Salvi et al.,32 and similar findings were recently confirmed as early as 12 days from therapy.35 Incomplete orbital tissue B-cell (and T-cell) depletion was observed in another two patients studied at approximately six months after RTX therapy,49,53 both also characterised by incomplete peripheral B-cell depletion. This may result from long lasting inactivation of autoreactive B cell-induction of inflammation by RTX, since in both patients GO became rapidly inactive and remained so on follow-up. Complete CD20+ cell depletion and either complete or near complete absence of CD3+ lymphocytes in the orbit may depend on the time elapsed from RTX therapy (see Figure 3). Of interest, we have recently observed significant infiltration of CD68+ macrophages after either full dose or low dose RTX.41 After performing further staining for CD1a and CD163, CD1a was found negative, indicating absence of dendritic cells, while CD163, a marker of type 2 macrophages, was well expressed and was particularly abundant in the two patients in whom RTX had been administered more recently.41 By comparison, control patients only had focal CD68+ and CD163+ cell infiltration. Recruitment of type 2 macrophages might be involved in the mechanism of action of RX in GO and would offer an explanation for its rapid effect. In the work of Khanna et al.,35 GO improvement and stabilisation after RTX was also associated with the detection of abundance of CD25 cells (T regs) in the peripheral blood, which have been shown to be predictive of RTX therapeutic success in rheumatoid arthritis.54

What is B-cell Depletion Showing us in Autoimmune Disease?
Based on the evidence obtained with RTX therapy in both animals and humans, B cells may contribute most significantly to the initiation of disease, as was observed early in the course of diabetes in non-obese diabetic (NOD) mice,55 in which it was not possible to reverse disease progression once inflammation had begun. This is because B-cell depletion in vivo has been shown to significantly decrease autoantigen-specific CD4+ T-cell proliferation in NOD mice, but not to inhibit T-cell expansion once fully initiated.2 More studies are needed to determine the significance of B-cell depletion therapy in humans by comparison to experimental animal models. B cells, T cells, and autoantibodies are known to be all involved in autoimmune disease pathogenesis, with B cells likely to contribute the most during early disease, while T-cell activation and autoantibody production may independently mediate disease progression.2 Based on the preliminary observations herein reviewed, an optimal strategy for controlling the progression of GO would be to pursue B-cell depletion shortly after diagnosis and perhaps not as a therapeutic option only when standard immunosuppression has failed. In addition, patients with other autoimmune disease like RA are almost always treated with RTX in combination with standard immunosuppressive drugs. The combination of RTX with other immunosuppressants, e.g. glucocorticoids in GO may more consistently suppress the immune system than B-cell depletion alone, although we do not know if this would bear a greater risk of more severe side effects. While B-cell depletion will affect autoantigen-specific T-cell activation and autoantibody synthesis, immunosuppression will interfere with the clonal expansion of autoreactive lymphocytes and synergistically decrease disease progression. Further understanding of the relative role of B and T cells, as well as autoantibodies, in each autoimmune disease will be critical for optimising future treatment strategies.

Article Information:
Disclosure

The authors have no conflicts of interest to declare.

Correspondence

Mario Salvi, MD, Endocrine Unit, Department of Medical Sciences (Padiglione Granelli), University of Milan, Fondazione Ca’ Granda IRCCS, Via Sforza 35, 20122 Milan, Italy. E: mario@mariosalvinet.it

Received

2011-07-07T00:00:00

References

  1. Lipsky PE, Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity, Nat Immunol, 2001;2:764–6.
  2. Bouaziz JD, Yanaba K, Venturi GM, et al., Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice, Proc Natl Acad Sci USA, 2007;104:20882–7.
  3. Yanaba K, Bouaziz JD, Matsushita T, et al., B-lymphocyte contributions to human autoimmune disease, Immunol Rev, 2008;223:284–99.
  4. Martin F, Chan AC, Pathogenic roles of B cells in human autoimmunity: insights from the clinic, Immunity, 2004;20:517–27.
  5. Ho F, Lortan JE, MacLennan IC, Khan M, Distinct short-lived and long-lived antibody-producing cell populations, Eur J Immunol, 1986;16:1297–301.
  6. Takahashi Y, Dutta PR, Cerasoli DM, Kelsoe G, In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl) acetyl.V. Affinity maturation develops in two stages of clonal selection, J Exp Med, 1998;187:885–95.
  7. DiLillo DJ, Hamaguchi Y, Ueda Y, et al., Maintenance of longlived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice, J Immunol, 2008; 180:361–71.
  8. Abbas AK, Lichtman AH, Pober JS (eds), B cell activation and antibody production. In: Cellular and Molecular Immunology, Philadelphia: W.B. Saunders Co.,1991;186–203.
  9. Kurt-Jones EA, Liano D, HayGlass KA, et al., The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice, J Immunol, 1988;140:3773–8.
  10. Constant S, Schweitzer N, West J, et al., Lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo, J Immunol, 1995;155:3734–41.
  11. Tumanov A, Kuprash D, Lagarkova M, et al., Distinct role of surface lymphotoxin expressed by B cells in the organization of secondary lymphoid tissues, Immunity, 2002;17:239–50.
  12. Gonzalez M, Mackay F, Browning JL, et al., The sequential role for lymphotoxin and B cells in the development of splenic follicles, J Exp Med, 1998;187:997–1007.
  13. Harris DP, Haynes L, Sayles PC, et al., Reciprocal regulation of polarized cytokine production by effector B and T cells, Nat Immunol, 2000;1:475–82.
  14. Fillatreau S, Sweenie CH, McGeachy MJ, et al., B cells regulate autoimmunity by provision of IL-10, Nat Immunol, 2002;3:944–50.
  15. Asadullah K, Sterry W, Volk HD, Interleukin-10 therapy-review of a new approach, Pharmacol Rev, 2003;55:241–69.
  16. Goetz M, Atreya R, Ghalibafian M, et al., Exacerbation of ulcerative colitis after rituximab salvage therapy, Inflamm Bowel Dis, 2007;13:1365–8.
  17. El Fassi D, Nielsen CH, Kjeldsen J, et al., Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves’ disease, Gut, 2008;57:714–5.
  18. Dass S, Vital EM, Emery P, Development of psoriasis after B cell depletion with rituximab, Arthritis Rheum, 2007;56:2715–8.
  19. Stashenko P, Nadler LM, Hardy R, Schlossman SF, Characterization of a human B lymphocyte-specific antigen, J Immunol, 1980;125:1678–85.
  20. Edwards JC, Leandro MJ, Cambridge GB, Lymphocyte depletion in rheumatoid arthritis: targeting of CD20, Curr Dir Autoimmun, 2005;8:175–92.
  21. Hoyer BF, Manz RA, Radbruch A, Hiepe F, Long-lived plasma cells and their contribution to autoimmunity, Ann N Y Acad Sci, 2005;1050:124–33.
  22. Ahuja A, Anderson SM, Khalil A, Shlomchik MJ, Maintenance of the plasma cell pool is independent of memory B cells, Proc Natl Acad Sci, 2008;105:4802–7.
  23. Roll P, Palanichamy A, Kneitz C, et al., Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis, Arthritis Rheum, 2006; 54:2377–86.
  24. Thurlings RM, Vos K, Wijbrandts CA, et al., Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response, Ann Rheum Dis, 2008;67:917–25.
  25. Thurlings RM, Vos K, Gerlag DM, Tak PP, Disease activityguided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial non responders versus initial responders, Arthritis Rheum, 2008;58:3657–64.
  26. Cartron G, Trappe RU, Solal-Céligny P, Hallek M, Interindividual variability of response to rituximab : from biological origins to individualized therapies, Clin Cancer Res, 2011;17:19–30.
  27. Pescovitz MD, Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action, Am J Transplant, 2006;6:859–66.
  28. Edwards JC, Leandro MJ, Cambridge GB, Lymphocyte depletion therapy with rituximab in rheumatoid arthritis, Rheum Dis Clin North Am, 2004;30:393–403.
  29. Descotes J, Immunotoxicity of monoclonal antibodies, MAbs, 2009;1:104–11.
  30. Food and Drug Administration, FDA Public Health Advisory: life-threatening brain infection in patients with systemic lupus erythematosus after Rituxan (rituximab) treatment, (2006) Available at: www.fda.gov/cder/drug/ (accessed 31 August 2011).
  31. Molloy ES, Calabrese LH, Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev, 2008; 8:144–6.
  32. Salvi M, Vannucchi G, Campi I, et al., Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression, Eur J Endocrinol, 2006;154:511–7.
  33. El Fassi D, Nielsen CH, Hasselbalch HC, Hegedus L, Treatment-resistant severe, active Graves’ ophthalmopathy successfully treated with B lymphocyte depletion, Thyroid, 2006;16:7.
  34. Salvi M, Vannucchi G, Campi I, et al., Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study, Eur J Endocrinol, 2007;156:33–40.
  35. Khanna D, Chong KK, Afifiyan NF, et al., Rituximab treatment of patients with severe, corticosteroid-resistant thyroidassociated ophthalmopathy, Ophthalmology, 2010;117:133–9.
  36. Silkiss RZ, Reier A, Coleman M, Lauer S, Rituximab for Thyroid Eye Disease, Ophthal Plast Reconstr Surg; 2010;26:310–4.
  37. Dolman PJ, Rootman J, VISA classification for Graves orbitopathy, Ophthal Plast Reconstr Surg, 2006;22:319–24.
  38. Mitchell AL, Morris M, Johnson K, et al., Rituximab for refractory Graves’ orbitopathy: initial experience in Newcastle, 14Th International Thyroid Congress, Paris, September 11–16th, 2010: P0403.
  39. Madaschi S, Rossini A, Formenti I, et al., Treatment of thyroid-associated orbitopathy with rituximab – a novel therapy for an old disease: case report and literature review, Endocr Pract, 2010; 16:677–85.
  40. Krassas GE, Stafilidou A, Boboridis KG, Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids, Clin Endocrinol, 2010;72:853–5.
  41. Salvi M, Vannucchi G, Currò N, et al., A small dose of rituximab may be sufficient to treat Graves’ orbitopathy: new insights into the mechanism of action, Arch Ophthalmol, 2011: in press.
  42. El Fassi D, Nielsen CH, Bonnema SJ, et al., B lymphocyte depletion with the monoclonal antibody Rituximab in Graves’ disease. A controlled pilot study, J Clin Endocrinol Metab, 2007;92:1769–72.
  43. Heemstra KA, Toes RE, Sepers J, et al., Rituximab in relapsing Graves’ disease, a phase II study, Eur J Endocrinol, 2008;159:609–15.
  44. El Fassi D, Banga JP Gilbert JA, et al., Treatment of Graves’ disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies, Clin Immunol, 2009;130:252–8.
  45. Huang H, Benoist C, Mathis D, Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis, Proc Nat Acad Sci, 2010;107:4658–63.
  46. Smith TJ, B cell depletion in Graves’ disease: the right answer to the wrong question?, J Clin Endocrinol Metab, 2007;92:1769–72.
  47. Vannucchi G, Campi I, Bonomi M, et al., Rituximab treatment in patients with active Graves’ orbitopathy: effects on proinflammatory and humoral immune reactions, Clin Exp Immunol, 2010;161:436–43.
  48. Mikozami T, Salvi M, Wall JR, Eye muscle antibodies in Graves’ ophthalmopathy: pathogenic or secondary epiphenomenon?, J Endocrinol Invest, 2004; 27:221–9.
  49. Salvi M, Vannucchi G, Campi I, et al., Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates, Clin Immunol, 2009;131:360–5.
  50. Tedder TF, Engel P, CD20: a regulator of cell cycle progression of B lymphocytes, Immunol Today, 1994;15:450–4.
  51. Teng YK, Levarht EW, Hashemi M, et al., Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment, Arthritis Rheum, 2007;56:3909–18.
  52. El Fassi D, Clemmensen O, Nielsen CH, et al., Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves’ disease, J Clin Endocrinol Metab, 2007;92:3762–3.
  53. Nielsen JF, El Fassi D, Nielsen CH, et al., Evidence of orbital B and T cell depletion after rituximab therapy in Graves’ ophthalmopathy, Acta Ophthalmologica, 2009; 87:927–9.
  54. Boissier MC, Assier E, Biton J, et al., Regulatory T cells (Treg) in rheumatoid arthritis, Join Bone Spine, 2009;76:10–4.
  55. Xiu Y, Wong CP, Bouaziz JD, et al., B lymphocytes depletion by CD20 monoclonal antibody prevents diabetes in NOD mice despite isotype-specific differences in FcgR effector functions, J Immunol, 2008;180:2863–75.

Further Resources

Share this Article
Related Content In Thyroid Disorders
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72